一种响应刺激的基于微针的药物输送系统,用于癌症治疗
Hongyu Tang1,2, Xueqing Cheng1, Ling Liang1,3,4
1Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
Biomaterials science
|November 6, 2024
概括
响应刺激的微针 (MNs) 通过克服瘤微环境挑战,提供增强的抗癌药物递送. 这种智能方法提高了药物的生物可用性,并减少了系统性毒性,以有效治疗癌症.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 瘤微环境 (TME) 阻碍了有效的抗癌药物递送,降低了治疗疗效.
- 传统的药物管理途径 (口服,静脉注射) 可以导致显著的全身毒性 (肝脏,脏).
- 使用微针 (MNs) 通过皮肤递送药物为局部治疗提供了一个有希望的替代方案.
研究的目的:
- 审查用于癌症治疗的刺激响应微针 (MN) 系统的最新进展.
- 突出MN在克服TME障碍和改善药物输送方面的潜力.
- 探索响应性MNs对瘤特异性特征和生物信号的适应性.
主要方法:
- 对药物输送的先进微针 (MN) 技术的当前文献的审查.
- 对刺激反应机制的分析,使MNs能够与瘤微环境 (TME) 相互作用.
- 评估MNs提高药物的生物可用性和减少全身毒性的能力.
主要成果:
- 响应刺激的MN表现出高的机械强度,可以有效地穿透皮肤.
- 这些MN能够有效地将药物直接输送到瘤组织,从而提高生物可用性.
- 响应性MN可以适应TME生化变异,为向治疗量身定制药物释放.
结论:
- 响应式微针 (MN) 系统代表了癌症治疗智能药物输送的重大进步.
- 这种方法提供了一个有希望的策略,以克服瘤微环境 (TME) 的挑战,并改善治疗结果.
- 对智能MN药物输送系统的进一步研究有望为未来的瘤学临床应用提供潜力.
相关概念视频
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...